In The Spotlight
- 06 March 2017 - 08 March 2017
- The Intrepid Sea, Air and Space Museum
- The Times Center, New York
- 07 February 2017 - 09 February 2017
- PGA National Resort & Spa, Palm Beach Gardens, FL
- 05 May 2017 - 07 May 2017
- Bologna Fair Centre
- Bologna, Italy
- 07 November 2017 - 10 November 2017
- Shanghai New International Exhibition Centre (SNIEC)
- Shanghai ,China
- 15 May 2017 - 18 May 2017
- National Exhibition and Convention Center
- Shanghai, China
PharmAthene, Inc. and Altimmune, Inc., a privately-held immunotherapeutics company targeting infectious diseases, announced the signing of a definitive agreement for the merger of PharmAthene and Altimmune in an all-stock transaction.
Maverick Therapeutics Inc , an MPM Capital portfolio company, and Takeda Pharmaceutical Company Limited announced that they have entered a collaboration to develop Maverick’s T-cell engagement platform created specifically to improve the utility of T-cell redirection therapy for the treatment of cancer.
Takeda Pharmaceutical Company Limited and PvP Biologics, Inc announced a global agreement for the development of KumaMax, a novel enzyme designed to break down the immune-reactive parts of gluten in the stomach, thereby avoiding the painful symptoms and damage done in the small intestine from accidental gluten ingestion.
New clinical trials company, Interface Clinical Research, outlined a new model for running primary care clinical trials at their launch yesterday at the Royal Society in London.
Pluristem Therapeutics Inc , a leading developer of placenta-based cell therapy products, today announced that it has completed enrollment of all 172 patients in a multinational Phase II trial of its PLX-PAD cells in the treatment of intermittent claudication (IC), a peripheral artery disease (PAD).
Visterra, Inc , a clinical-stage biopharmaceutical company announced that the first patient was dosed in a Phase 2a clinical trial of VIS410, a monoclonal antibody in development for the treatment of hospitalized patients with influenza A, regardless of the viral strain.
Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products.
Biotech firms Prokarium and Probiomed have announced a collaboration to scale-up the manufacture of orally administered vaccines in a formulation that would enable stability at 40°C for several weeks.
Synpromics Ltd, the leading synthetic promoter and gene control company, is pleased to announce a research collaboration with GE Healthcare to jointly develop customised synthetic promoters optimised for GE Healthcare’s proprietary biopharmaceutical manufacturing platform.
The latest in rigid and flexible packaging materials for medical device and pharmaceutical applications will be featured by Tekni-Films, a Tekni-Plex company, at MD&M West, February 7-9, Anaheim Convention Center, Anaheim, Calif., in Booth 2027.
Klöckner Pentaplast will present the latest range of pharmaceutical packaging solutions and services at Pharmapack 2017 (Booth A30), February 1-2, 2017, in Paris, France.
Yokogawa Electric Corporation announces that it has developed an ISA100 Wireless™ based field wireless vibration sensor with the ability to quickly update data and a long battery life, and will release it in markets other than Japan on December 7.
WuXi AppTec, a leading global pharmaceutical, biotechnology and medical device open-access capability and technology platform announced that it has acquired HD Biosciences (HDB), a leading biology focused preclinical drug discovery contract research organization (CRO).
Moberg Pharma AB has now completed the acquisition of DermoPlast® Prestige Brands, Inc. in accordance with the terms announced on December 6. The purchase price was 47.6 million plus inventory value.
OncoGenex Pharmaceuticals, Inc , a publicly held oncology biopharmaceutical company, and Achieve Life Science, Inc , a privately held specialty pharmaceutical company, announced that they have entered into a definitive merger agreement under which OncoGenex will acquire Achieve in an all-stock transaction.
Type 2 diabetes awareness is rising in the United States. Public and private health leaders are now offering screenings and patient education sites that discuss “prediabetes,” to detect and treat the disease in its earliest stages.
Clinical research generates extensive amounts of data, yet most of it is siloed or generally unavailable to a larger pool of willing potential researchers.
Finding suitable patients to participate in clinical trials is a long complicated process taking months today.The emergence of electronic hospital records (EHRs) in a hospital information system (HIS) allows this process to be automated and accelerated.
Fresenius Medical Care, the world’s largest provider of dialysis products and services, today announced a leadership change in North America.
Alexion Pharmaceuticals Inc announced that the U.S. FDA has granted orphan drug designation (ODD) to ALXN1210, a highly innovative, longer-acting anti-C5 antibody that inhibits terminal complement, which is being evaluated for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH).
Hologic, Inc announced that the U.S. FDA has granted PMA approval for the Company's HIV-1 viral load monitoring assay. The Aptima® HIV-1 Quant assay is a nucleic acid amplification test for the quantitative detection of RNA from HIV in plasma specimens.